HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
29 May 2020 01:00 PM
RNS
Chi-Med to Discuss Data Presented at ASCO20
29 May 2020 07:00 AM
RNS
NDA Acceptance in China for Savolitinib
26 May 2020 07:00 AM
RNS
Chi-Med and BeiGene Enter Clinical Collaboration
14 May 2020 07:00 AM
RNS
Clinical Data to be Presented at ASCO20
11 May 2020 04:41 PM
RNS
Second Price Monitoring Extn
11 May 2020 04:36 PM
RNS
Price Monitoring Extension
11 May 2020 07:00 AM
RNS
Chi-Med to Attend Upcoming Investor Conferences
29 Apr 2020 11:45 AM
RNS
Grant of Share Options under Share Option Scheme
27 Apr 2020 02:00 PM
RNS
Result of AGM
22 Apr 2020 09:00 AM
RNS
Virtual Presentations of Surufatinib at AACR
21 Apr 2020 11:30 AM
RNS
Grant of LTIP Awards and Share Options
17 Apr 2020 07:00 AM
RNS
Surufatinib Granted FDA Fast Track Designations
31 Mar 2020 07:04 AM
RNS
China Phase II trial initiation in mesothelioma
25 Mar 2020 07:00 AM
RNS
Annual Financial Report
09 Mar 2020 07:00 AM
RNS
Vesting of awards under Long Term Incentive Plan
03 Mar 2020 02:18 PM
RNS
Form-20F Publication
03 Mar 2020 12:15 PM
RNS
Final Results and Clinical Update
25 Feb 2020 07:00 AM
RNS
Notice of Results
10 Feb 2020 07:00 AM
RNS
Phase II Savolitinib / Imfinzi® Combination Data
06 Feb 2020 04:35 PM
RNS
Price Monitoring Extension
06 Feb 2020 07:20 AM
RNS
Issue of Equity
04 Feb 2020 04:40 PM
RNS
Second Price Monitoring Extn
04 Feb 2020 04:35 PM
RNS
Price Monitoring Extension
31 Jan 2020 07:00 AM
RNS
Notice of Results
29 Jan 2020 07:25 AM
RNS
Holding(s) in Company
23 Jan 2020 07:35 AM
RNS
Pricing of US$110 Million Public Offering of ADSs
22 Jan 2020 07:00 AM
RNS
Chi-Med Announces Proposed Offering of ADSs
20 Jan 2020 10:40 AM
RNS
Positive SANET-p Phase III Clinical Trial Results
13 Jan 2020 07:00 AM
RNS
Chi-Med Starts Surufatinib+PD-1 Ph2 Combo Trial
06 Jan 2020 07:04 AM
RNS
Chi-Med to Present at JP Morgan Conference
31 Dec 2019 07:00 AM
RNS
Block Listing Six Monthly Return
31 Dec 2019 07:00 AM
RNS
Total Voting Rights
20 Dec 2019 07:00 AM
RNS
Surufatinib Granted Priority Review in China
12 Dec 2019 08:57 AM
RNS
Grant of share options
29 Nov 2019 08:56 AM
RNS
Total Voting Rights
28 Nov 2019 07:00 AM
RNS
Elunate® Included in China NRDL
25 Nov 2019 07:47 AM
RNS
Chi-Med Highlights Presentations at 2019 ESMO Asia
25 Nov 2019 07:00 AM
RNS
Surufatinib granted FDA orphan drug designation
11 Nov 2019 07:00 AM
RNS
Surufatinib China NDA acceptance
17 Oct 2019 07:26 AM
RNS
Chi-Med Ph II gastric cancer data for Savolitinib
10 Oct 2019 10:22 AM
RNS
Grant of share options under share option scheme
10 Oct 2019 09:00 AM
RNS
Innovent and Chi-Med Expand Global Collaboration
04 Oct 2019 07:11 AM
RNS
Chi-Med Phase I/Ib Trial of HMPL-523 in Lymphoma
03 Oct 2019 08:26 AM
RNS
Holding(s) in Company
30 Sep 2019 01:49 PM
RNS
Holding(s) in Company
30 Sep 2019 12:11 PM
RNS
Holding(s) in Company
30 Sep 2019 07:00 AM
RNS
Chi-Med Surufatinib Phase III data at ESMO
30 Sep 2019 07:00 AM
RNS
Total Voting Rights
25 Sep 2019 07:00 AM
RNS
Chi-Med Presents SANET-ep Phase III data at ESMO
18 Sep 2019 07:00 AM
RNS
Chi-Med Highlights Presentations at 2019 CSCO

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100

Latest directors dealings